Steve Kelsey, MB ChB, MD
Board of Directors
Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE:PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ:GERN), vice president of oncology at Genentech (part of the Roche Group) and medical director at Pharmacia / SUGEN (acquired by Pfizer). Dr. Kelsey has had key roles in the development of many oncology therapeutics including Sutent, Perjeta, Kadcycla, Erivedge and imetelstat.
Dr. Kelsey received his medical degrees from the University of Birmingham in the UK and trained as a hematologic oncologist at Barts and The London Hospital where he was a clinician-scientist focused on leukemias and lymphomas.